Journal of Hepatology
Volume 39 , Pages 3-25 , 2003

EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B: 13–14 September, 2002 Geneva, Switzerland Consensus statement (Long version)

  • The EASL Jury

      Affiliations

    • MEMBERS OF THE JURY: Roberto de Franchis, Italy; Antoine Hadengue, Switzerland; George Lau, China; Daniel Lavanchy, Switzerland; Anna Lok, USA; Neil McIntyre, UK; Alfonso Mele, Italy; Gustav Paumgartner, Germany; Antonello Pietrangelo, Italy; Juan Rodés, President, Spain; William Rosenberg, UK; Dominique Valla, Secretary, France
    • MEMBERS OF THE ORGANIZING COMMITTEE: Alfredo Alberti, Italy; Geoffrey Dusheiko, UK; Stephanos Hadziyannis, Greece; Patrick Marcellin, Coordinator, France; Mario Rizzetto, Italy; Didier Samuel, France; Daniel Shouval, Israel
    • CHAIRPERSONS & INVITED SPEAKERS: Alfredo Alberti, Italy; Miriam Alter, USA; Yves Benhamou, France; Paolo Bonanni, Italy; Feruccio Bonino, Italy; Flavia Bortolotti, Italy; Jordi Bruix, Spain; Maurizia Brunetto, Italy; Massimo Colombo, Italy; Graham Cooksley, Australia; Antonia Craxi, Italy; Valeer Desmet, Belgium; Philippe Duclos, Switzerland; Geoffrey Dusheiko, UK; Rafael Esteban, Spain; Patrizia Farci, Italy; Giovanna Fattovich, Italy; Carlo Ferrari, Italy; Stephanos Hadziyannis, Greece; Jenny Heathcote, Canada; Jay Hoofnagle, USA; Yun-Fan Liaw, Taiwan; Stephen Locarnini, Australia; Michael Manns, Germany; Patrick Marcellin, France; Pem Namgyal, Switzerland; Nikolai Naoumov, UK; Jean-Michel Pawlotsky, France; Robert Perrillo, USA; Stanislas Pol, France; Patrizia Pontisso, Italy; Giovanni Raimondo, Italy; Mario Rizzetto, Italy; Michael Roggendorf, Germany; Didier Samuel, France; Solko Schalm, The Netherlands; Daniel Shouval, Israel; Howard Thomas, UK; Christian Trépo, France; Pierre Van Damme, Belgium; Hans Will, Germany; Theresa Wright, USA; Stephan Zeuzem, Germany; Fabien Zoulim, France
    • MEMBERS OF THE EASL SCIENTIFIC COMMITTEE: Jordi Bruix, Scientific Secretary, Spain; Chris Day, UK; Massimo Levrero, Italy; Frederick Nevens, Belgium; Didier Samuel, France; Cihan Yurdaydin, Turkey

References 

  1. Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13:S47–S49
  2. Gay N, Edmunds W, Bah E, Nelson C. Estimating the global burden of hepatitis B. Geneva: World Health Organization, Department of Vaccines and Biologicals; 2001;
  3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156
  4. FitzSimons D, Van Damme P, Emiroglu N, Godal T, Kane M, Malyavin A, et al.  Strengthening immunization systems and introduction of hepatitis B vaccine in central and eastern Europe and the newly independent states. Vaccine. 2002;20:1475–1479
  5. Margolis HS, Alter MJ, Hadler S. Viral hepatitis. In:  Evans A,  Kaslow R editor. Viral infections of humans. 4th ed. New York: Plenum; 1997;p. 363–418
  6. Rosina F, Conoscitore P, Cuppone R, Rocca G, Giuliani A, Cozzolongo R, et al.  Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology. 1999;117:161–166
  7. Metcalf M, Brown N, Peterson S, Feld A, Gale F, Kirk J, et al. Health care costs associated with chronic hepatitis B. Am J Health Syst Pharm. 1999;56:232–236
  8. Harbarth S, Szucs T, Berger K, Jilg W. The economic burden of hepatitis B in Germany. Eur J Epidemiol. 2000;16:173–177
  9. Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol. 2001;16:301–308
  10. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ. 2001;10:751–774
  11. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603
  12. Chang MH. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol. 2000;15:E16–E19
  13. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92:1844–1850
  14. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘occult’?. Hepatology. 2001;34:194–203
  15. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839–1843
  16. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–1022
  17. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527
  18. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759–768
  19. Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg. 1998;61:219–223
  20. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312–323
  21. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617–624
  22. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263–270
  23. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al.  The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118:191–194
  24. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13:627–631
  25. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051–1054
  26. Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, et al.  Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28:231–236
  27. Smedile A, Rizzetto M, Gerin JL. Advances in hepatitis D virus biology and disease. In:  Boyer J,  Ockner R editor. Progress in liver disease. vol. 12:Philadelphia, PA: Saunders; 1994;p. 157–175
  28. Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Yamashiro T, Maeshiro T, et al.  Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection. J Med Virol. 2001;65:478–484
  29. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al.  Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930–938
  30. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al.  Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294–298
  31. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, et al.  The long-term course of chronic hepatitis B. Hepatology. 1999;30:257–264
  32. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, et al.  Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology. 1989;10:198–202
  33. Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology. 1988;8:1651–1654
  34. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554–559
  35. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, et al.  Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1994;21:656–666
  36. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al.  Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21:77–82
  37. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145:1039–1047
  38. Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus- related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002;34:569–572
  39. Chung HT, Lai CL, Lok AS. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology. 1995;22:25–29
  40. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al.  Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27:1213–1219
  41. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al.  Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10
  42. Decker R. Diagnosis of acute and chronic hepatitis. In:  Zuckermann A,  Thomas H editor. Viral hepatitis. London: Churchill Livingstone; 1998;p. 201–215
  43. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002;122:1554–1568
  44. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology. 2001;120:1828–1853
  45. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002;35:1274–1276
  46. Ferrell L, Thiese N, Scheuer P. Acute and chronic viral hepatitis. In:  McSween R,  Burt A,  Portmann B,  Ishak K,  Scheuer P,  Anthony P editor. Pathology of the liver. 4th ed. London: Churchill Livingstone; 2002;p. 313–362
  47. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495–500
  48. Buckley A, Petrunia D. Practice guidelines for liver biopsy. Canadian Association of Gastroenterology. Can J Gastroenterol. 2000;14:481–482
  49. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut. 1999;45(Suppl 4):IV1–IV11
  50. Mas A, Rodes J. Fulminant hepatic failure. Lancet. 1997;349:1081–1085
  51. Maddrey WC. Hepatitis B an important public health issue. Clin Lab. 2001;47:51–55
  52. Shiraki K. Perinatal transmission of hepatitis B virus and its prevention. J Gastroenterol Hepatol. 2000;15:E11–E15
  53. Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods. 1987;17:69–79
  54. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al.  Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. J Infect Dis. 2002;185:713–719
  55. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am. 1990;74:1529–1541
  56. Goldmann DA. Blood-borne pathogens and nosocomial infections. J Allergy Clin Immunol. 2002;110:S21–S26
  57. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull WHO. 1999;77:789–800
  58. Puro V, De Carli G, Scognamiglio P, Porcasi R, Ippolito G. Risk of HIV and other blood-borne infections in the cardiac setting: patient-to-provider and provider-to-patient transmission. Ann N Y Acad Sci. 2001;946:291–309
  59. Mahoney FJ, Stewart K, Hu H, Coleman P, Alter MJ. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med. 1997;157:2601–2605
  60. Gerlich WH, Caspari G. Hepatitis viruses and the safety of blood donations. J Viral Hepat. 1999;6(Suppl 1):6–15
  61. Rosen HR, Martin P. Hepatitis B and C in the liver transplant recipient. Semin Liver Dis. 2000;20:465–480
  62. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, et al.  Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis. 2000;181:413–418
  63. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. J Am Med Assoc. 1996;276:906–908
  64. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–1859
  65. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med. 1992;92:254–256
  66. Zipp F, Weil JG, Einhaupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med. 1999;5:964–965
  67. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci. 2001;8:237–247
  68. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al.  The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. J Am Med Assoc. 1990;263:1218–1222
  69. Minuk GY, Bohme CE, Bowen TJ. Passive and active immunization against hepatitis B virus infection: optimal scheduling in healthy young adults. Clin Invest Med. 1989;12:175–180
  70. Esteban JI, Genesca J, Esteban R, Hernandez JM, Seijo G, Buti M, et al.  Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. J Med Virol. 1986;18:381–391
  71. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2:1099–1102
  72. Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JY, Chen GH, et al.  Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis. 1985;152:817–822
  73. Tine F, Liberati A, Craxi A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a meta- analysis of the published literature. J Hepatol. 1993;18:154–162
  74. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30:770–774
  75. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186–194
  76. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102:2091–2097
  77. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al.  Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719–727
  78. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207–210
  79. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–1847
  80. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al.  Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35:1528–1535
  81. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology. 1999;29:1581–1586
  82. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29:1306–1310
  83. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al.  Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211–217
  84. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000;32:1106–1110
  85. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al.  Treatment of chronic hepatitis D with interferon alpha-2a. N Engl J Med. 1994;330:88–94
  86. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al.  Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257–263
  87. Wedemeyer H, Pethig K, Manns MP, Boker KH. Hepatitis B infection in heart transplant patients. Gastroenterology. 2001;120:1311–1313
  88. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17:394–398
  89. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, et al.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702–709
  90. Lai CL, Lin HJ, Lau JN, Flok AS, Wu PC, Chung HT, et al.  Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med. 1991;78:155–163
  91. Jonas MM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al.  Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002;346:1706–1713
  92. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther. 2001;15:1899–1905
  93. Cooksley WGE, Pirathvisuth T, Wang YJ, Mahachi V, Chao YC, Tanwandee T, et al.  Evidence for the efficacy of Peg-Interferon alpha 2A (40Kd) (Pegasys) in the treatment of HBeAntigen positive chronic hepatitis B and impact of baseline factors [abstract]. J Hepatol. 2002;36:8
  94. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46:562–568
  95. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, et al.  Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology. 2001;34:573–577
  96. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, et al.  Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol. 2002;36:799–804
  97. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256–1263
  98. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–68
  99. Marcellin P, Goodmann Z, Chang TT, Lim SG, Tong M, Sievert W, et al.  Adefovir Dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  100. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002;36:1425–1430
  101. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon α-for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427
  102. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alpha. Gastroenterology. 1997;113:1660–1667
  103. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971–975
  104. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha. Gastroenterology. 1993;105:1833–1838
  105. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis Be antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806
  106. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al.  Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000;32:828–834
  107. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B [abstract]. J Gastroenterol Hepatol. 2001;16:44
  108. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527–1532
  109. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172–180
  110. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27:1670–1677
  111. Schiff ER, Karayalcin S, Grimm I, Perillo R, Dienstag J, Husa P, et al.  A placebo-controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [abstract]. Hepatology. 1998;28:388A
  112. Wong VWS, Chan HLY, Wong ML, Leung N. Is it safe to stop lamivudine after emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? [abstract]. J Hepatol. 2002;36:177
  113. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al.  Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 2000;32:129–134
  114. Peters M, Hann WH, Martin P, Heathcote EJ, Buggisch P, Moorat AE, et al.  Adefovir dipivoxil alone and in combination with lamivudine suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis [abstract]. Hepatology. 2002;36:374A
  115. Hadziyannis S, Tassopolous N, Heathcote EJ, Chang TT, Kitis G, Rizzetto T, et al.  Adefovir Dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis. N Engl J Med. 2003;348:800–807
  116. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg- negative precore mutant HBV liver disease. Hepatology. 2002;36:219–226
  117. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al.  Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 2000;32:1145–1153
  118. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al.  Low-dose, titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109:908–916
  119. Schiff ER, Lai CL, Neuhaus P, Tillmann H, Samuel D, Villeneuve JP, et al.  Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation with lamivudine resistant hepatitis B virus [abstract]. Hepatology. 2002;36(Pt 2):371A
  120. Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut. 2001;49:860–863
  121. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut. 2001;49:436–440
  122. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al.  Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 1996;125:705–712
  123. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999;180:607–613
  124. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis. 2002;186:1844–1847

PII: S0168-8278(03)00378-7

doi: 10.1016/S0168-8278(03)00378-7

Journal of Hepatology
Volume 39 , Pages 3-25 , 2003

Article Tools

* Image Usage & Resolution